Wells Fargo & Company Aurinia Pharmaceuticals Inc. Transaction History

Wells Fargo & Company

  • $433 Billion
  • Q4 2024

A detailed history of Wells Fargo & Company transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 72,084 shares of AUPH stock, worth $587,484. This represents 0.0% of its overall portfolio holdings.

Number of Shares
72,084
Previous 63,088 14.26%
Holding current value
$587,484
Previous $462,000 40.04%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
BUY
$6.75 - $10.44 $60,723 - $93,918
8,996 Added 14.26%
72,084 $647,000
Q3 2024

Nov 13, 2024
SELL
$5.32 - $7.33 $19,774 - $27,245
-3,717 Reduced 5.56%
63,088 $462,000
Q2 2024

Aug 13, 2024
BUY
$4.81 - $5.78 $22,169 - $26,640
4,609 Added 7.41%
66,805 $381,000
Q1 2024

May 10, 2024
SELL
$4.93 - $9.31 $490,682 - $926,624
-99,530 Reduced 61.54%
62,196 $311,000
Q4 2023

Feb 09, 2024
SELL
$7.13 - $9.49 $211,932 - $282,080
-29,724 Reduced 15.53%
161,726 $1.45 Million
Q3 2023

Nov 13, 2023
SELL
$7.77 - $12.27 $169,121 - $267,068
-21,766 Reduced 10.21%
191,450 $1.49 Million
Q2 2023

Aug 15, 2023
BUY
$8.96 - $11.69 $293,153 - $382,473
32,718 Added 18.13%
213,216 $2.06 Million
Q1 2023

May 12, 2023
BUY
$5.94 - $11.27 $165,458 - $313,925
27,855 Added 18.25%
180,498 $1.98 Million
Q4 2022

Feb 13, 2023
SELL
$4.11 - $8.14 $808,786 - $1.6 Million
-196,785 Reduced 56.32%
152,643 $659,000
Q3 2022

Nov 14, 2022
SELL
$6.66 - $12.39 $196,203 - $365,009
-29,460 Reduced 7.78%
349,428 $2.63 Million
Q2 2022

Aug 12, 2022
SELL
$8.95 - $12.8 $913,016 - $1.31 Million
-102,013 Reduced 21.21%
378,888 $3.81 Million
Q1 2022

May 16, 2022
SELL
$10.05 - $22.48 $161,724 - $361,748
-16,092 Reduced 3.24%
480,901 $5.95 Million
Q4 2021

Feb 14, 2022
SELL
$17.78 - $33.08 $1.46 Million - $2.71 Million
-81,881 Reduced 14.14%
496,993 $11.4 Million
Q3 2021

Nov 15, 2021
SELL
$10.93 - $23.55 $2.29 Million - $4.93 Million
-209,409 Reduced 26.57%
578,874 $12.8 Million
Q2 2021

Aug 16, 2021
BUY
$10.0 - $14.52 $244,620 - $355,188
24,462 Added 3.2%
788,283 $10.2 Million
Q1 2021

May 13, 2021
BUY
$12.3 - $18.73 $1.2 Million - $1.82 Million
97,224 Added 14.59%
763,821 $9.92 Million
Q4 2020

Feb 09, 2021
BUY
$12.94 - $16.05 $3.73 Million - $4.63 Million
288,250 Added 76.19%
666,597 $9.22 Million
Q3 2020

Nov 05, 2020
BUY
$13.19 - $16.66 $2.66 Million - $3.36 Million
201,880 Added 114.4%
378,347 $5.57 Million
Q2 2020

Aug 13, 2020
SELL
$14.12 - $18.33 $3.38 Million - $4.39 Million
-239,386 Reduced 57.57%
176,467 $2.87 Million
Q1 2020

May 14, 2020
BUY
$11.34 - $21.46 $4.72 Million - $8.92 Million
415,853 New
415,853 $6.03 Million

Others Institutions Holding AUPH

# of Institutions
227
Shares Held
58.9M
Call Options Held
949K
Put Options Held
1.51M
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.16B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email